Fundraising Fox
Nemus Bioscience
NASDAQ: SKYECosta Mesa, US · Founded 2011 · Nevada corporation
Find your way into Nemus Bioscience
Sign up to see every warm intro you have to Nemus Bioscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nemus Bioscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Skye Bioscience is a biotechnology company developing drugs that target the CB1 receptor to treat obesity and other metabolic diseases. Its lead candidate, nimacimab, is a CB1 receptor inhibitor in clinical development.
Founders & leadership
EM
Elizabeth M. BereczExecutive
JB
John B. HollisterExecutive
BS
Brian S. MurphyExecutive
CN
Cosmas N. LykosNamed on SEC filing
Board
GW
Gerald W. McLaughlinBoard director
Reported raises · per SEC filings
Form D private placements$168.4M disclosed across 11 of 13 rounds · 1900–2024
▶$40MraisedMar 2024 · 13 investors · BiotechnologyRule 506(b)
▶$40MraisedMar 2024 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Margaret DalesandroDirector
- Punit DhillonExecutive Officer, Director
- Kaitlyn ArsenaultExecutive Officer
- Annalisa JenkinsDirector
- Praveen TyleDirector
- Deborah CharychDirector
- Paul GraysonDirector
- Andrew SchwabDirector
- Keith WardDirector
- Offering amount
- $40M
- Amount sold
- $40M
- Sales commissions
- $2.4M
- Placement agents
- Oppenheimer & Co. Inc., Piper Sandler & Co
- First sale
- Mar 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$50MraisedFeb 2024 · 11 investors · BiotechnologyRule 506(b)
▶$50MraisedFeb 2024 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Keith WardDirector
- Margaret DalesandroDirector
- Kaitlyn ArsenaultExecutive Officer
- Paul GraysonDirector
- Praveen TyleDirector
- Punit DhillonExecutive Officer, Director
- Deborah CharychDirector
- Andrew SchwabDirector
- Offering amount
- $50M
- Amount sold
- $50M
- Sales commissions
- $3.5M
- Placement agents
- Oppenheimer & Co. Inc., Piper Sandler & Co
- First sale
- Jan 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$62.3MraisedAug 2023 · 12 investors · BiotechnologyRule 506(b)
▶$62.3MraisedAug 2023 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Praveen TyleDirector
- Kaitlyn ArsenaultExecutive Officer
- Deborah CharychDirector
- Keith WardDirector
- Punit DhillonExecutive Officer, Director
- Margaret DalesandroDirector
- Andrew SchwabDirector
- Paul GraysonDirector
- Offering amount
- $62.3M
- Amount sold
- $62.3M
- First sale
- Aug 2023
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2MraisedNov 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$2MraisedNov 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Douglas A. CesarioExecutive Officer
- Punit DhillonDirector
- Avtar DhillonDirector
- Brian S. MurphyExecutive Officer, Director
- James L. HeppellDirector
- Offering amount
- $32.5M
- Amount sold
- $2M
- First sale
- Nov 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$4.2MraisedFeb 2018 · 2 investors · PharmaceuticalsRule 506(b)
▶$4.2MraisedFeb 2018 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James L. HeppellDirector
- Brian S. MurphyExecutive Officer, Director
- Elizabeth M. BereczExecutive Officer
- Punit DhillonDirector
- Offering amount
- $8.6M
- Amount sold
- $4.2M
- First sale
- Jan 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2MraisedNov 2017 · 2 investors · PharmaceuticalsRule 506(b)
▶$2MraisedNov 2017 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Douglas S. IngramDirector
- Gerald W. McLaughlinDirector
- Brian S. MurphyExecutive Officer, Director
- Cosmas N. LykosExecutive Officer, Director
- Elizabeth M. BereczExecutive Officer
- Thomas A. GeorgeDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Nov 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.2MraisedJan 2017 · 5 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedJan 2017 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brian S. MurphyExecutive Officer
- Yosbani MendezPromoter
- Thomas A. GeorgeDirector
- Douglas S. IngramDirector
- Cosmas N. LykosExecutive Officer, Director
- Francicso MendezPromoter
- Gerald W. McLaughlinDirector
- Elizabeth M. BereczExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.2M
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Jan 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$500KraisedNov 2016 · 1 investors · PharmaceuticalsRule 506(b)
▶$500KraisedNov 2016 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Yosbani MendezPromoter
- Douglas S. IngramExecutive Officer, Director
- Cosmas N. LykosExecutive Officer, Director
- Brian S. MurphyExecutive Officer
- Elizabeth M. BereczExecutive Officer
- Francicso MendezPromoter
- Gerald W. McLaughlinDirector
- Thomas A. GeorgeDirector
- Offering amount
- $500K
- Amount sold
- $500K
- Sales commissions
- $50K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Oct 2016
- Incorporated
- Corporation, Nevada, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$11Mvaluation at IPOAug 2020 · $0.06/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Nemus Bioscience do?
- Skye Bioscience is a biotechnology company developing drugs that target the CB1 receptor to treat obesity and other metabolic diseases. Its lead candidate, nimacimab, is a CB1 receptor inhibitor in clinical development.
- How much funding has Nemus Bioscience raised?
- Nemus Bioscience has disclosed $168.4M raised across 11 of its 13 known rounds.
- Where is Nemus Bioscience headquartered?
- Nemus Bioscience is headquartered in Costa Mesa, US.